In this session, Dr. Ming Zhou addresses the value of knowing the BRCA status of advanced prostate cancer patients in their disease journey and how BRCA1/2 testing helps identify a greater number of patients who can benefit from PARPi therapies.
Speaker name: Dr. Ming Zhou
Dr. Ming Zhou is the Pathologist-in-Chief and Chair of the Tufts Medical Center Department of Pathology, and Professor and Chair of the Department of Anatomic and Clinical Pathology at Tufts University School of Medicine in Boston, MA. He graduated summa cum laude from Fudan University Medical School in Shanghai, China. He completed his pathology residency training at the University of Michigan and a fellowship in Urological and Kidney Diseases at the Johns Hopkins Hospital. He previously held faculty and administrative positions at Cleveland Clinic, New York University, and the University of Texas Southwestern Medical Center in Dallas.
Dr. Zhou has devoted his clinical and research effort to diagnostic urological pathology, and the discovery and validation of tumor markers for urological malignancy. He has authored 196 peer-reviewed articles and numerous book chapters and co-authored 5 textbooks on urological and prostate pathology, including the AFIP prostate fascicle, and three of them in the 2nd edition. He frequently lectures at national and international meetings on urological pathology. He was the speaker at the California tumor tissue registry meeting in 2014 and 2022, and the co-course director of the prostate cancer long course at the 2018 USCAP annual meeting. He was a faculty of three USCAP short courses and five IM courses. He is currently a member of the USCAP Board of Directors, and the President of the Genitourinary Pathology Society (GUPS), an international organization for urological pathologists.